These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8543517)

  • 1. Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.
    Connor DF; Benjamin S; Ozbayrak KR
    J Am Acad Child Adolesc Psychiatry; 1995 Nov; 34(11):1490-4. PubMed ID: 8543517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic withdrawal dyskinesia [proceedings].
    Escobar JI; Tuason VB
    Psychopharmacol Bull; 1979 Apr; 15(2):71-4. PubMed ID: 34845
    [No Abstract]   [Full Text] [Related]  

  • 3. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.
    Gualtieri CT; Quade D; Hicks RE; Mayo JP; Schroeder SR
    Am J Psychiatry; 1984 Jan; 141(1):20-3. PubMed ID: 6140865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment.
    Perényi A; Frecska E; Bagdy G; Révai K
    Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.
    Meltzer HY; Lee MA; Ranjan R; Mason EA; Cola PA
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):176-87. PubMed ID: 8935814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
    Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
    J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal syndromes associated with antipsychotic drugs.
    Gardos G; Cole JO; Tarsy D
    Am J Psychiatry; 1978 Nov; 135(11):1321-4. PubMed ID: 30287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening neuroleptic withdrawal emergent syndrome resembling status dystonicus.
    Pugin D; Bally J; Horvath J; Pollak P; Gasche Y; Burkhard PR
    Parkinsonism Relat Disord; 2017 Feb; 35():96-97. PubMed ID: 27914829
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing epidemiology of tardive dyskinesia: an overview.
    Jeste DV; Wyatt RJ
    Am J Psychiatry; 1981 Mar; 138(3):297-309. PubMed ID: 6110344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M
    Psychiatr Pol; 1999; 33(1):69-81. PubMed ID: 10786216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
    Diaz A; Fouilloux C; Ortiz S
    Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients.
    Janno S; Holi M; Tuisku K; Wahlbeck K
    Am J Psychiatry; 2004 Jan; 161(1):160-3. PubMed ID: 14702266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptics in pediatric psychiatry.
    Whitaker A; Rao U
    Psychiatr Clin North Am; 1992 Mar; 15(1):243-76. PubMed ID: 1347940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia: managing a common neuroleptic side effect.
    Jeste DV; Krull AJ; Kilbourn K
    Geriatrics; 1990 Dec; 45(12):49-54. PubMed ID: 1979304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with neuroleptics in the acute phase of mental disease.
    Dencker SJ
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):32-4. PubMed ID: 14332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.